The U.S. FDA has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11)—the first drug for PET imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer.
Category: Nuclear Medicine
In a head-to-head comparison, 68Ga-DOTA-JR11 PET/CT performed better than 68Ga-DOTATATE PET/CT in detecting liver metastases.Read More
PSMA-targeted 18F-DCFPyL-PET/CT imaging demonstrated excellent diagnostic performance in men with biochemically relapsed prostate cancer.Read More
Novel, fully digital, high-resolution PET/CT imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment.Read More
Myocardial blood flow and myocardial flow reserve have been identified as accurate indicators for graft failure after cardiac transplantation, according to a new study published in The Journal of Nuclear Medicine.Read More
The newly developed imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases.Read More